Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triaryl dimethylpiperazine dihydrochloride
- Development stage
- Preclinical
- Lead developer
- Yunnan Baiyao
- Modality
- Small Molecules
- Administration
- Subcutaneous, Intravenous, Intrathecal, Intraperitoneal, Parenteral
01
Overview
Triaryl dimethylpiperazine dihydrochloride is a small molecule crystalline polymorph being developed by Yunnan Baiyao Group. The compound belongs to a chemical class of highly selective delta-opioid receptor (DOR) agonists, with SNC80 being the most prominent representative of this scaffold. Yunnan Baiyao has filed patents (such as CN111606884A) specifically covering stable crystalline forms of the dihydrochloride salt of this compound. Delta-opioid receptor agonists are primarily investigated for their potential in treating chronic pain, treatment-resistant depression, and anxiety, as well as for their neuroprotective effects in conditions like Parkinson's disease. The development of specific polymorphs is typically aimed at optimizing the drug's stability, solubility, and pharmacokinetic profile for clinical applications. The program is currently in the preclinical stage.
- Other names
- 4-[(R)-(2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide dihydrochlorideTriaryl Dimethylpiperazine Dihydrochloride Polymorph
02
Targets
DOR (Opioid Receptor Delta 1)MOR-DOR (Mu-opioid receptor – delta-opioid receptor heteromer)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on triaryl dimethylpiperazine dihydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triaryl dimethylpiperazine dihydrochloride.